Answering the Questions on Switching ART With Virologic Suppression

CCO Infectious Disease Podcast

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:

• Switching with prior or unknown resistance
  • Data on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studies
  • The impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 study
  • A post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistance
  • Data from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184V
  • A retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS Cohort
• Switching to long-acting ART
  • Guidance on candidates for LA CAB + RPV
  • Data on risk factors for virologic failure with LA CAB + RPV
• Considering an ART switch after weight gain
  • Data on weight gain after ART initiation by ARV class and drug
  • Mean change in weight by sex at Week 96 in the ADVANCE study
  • DHHS guideline recommendations regarding weight gain with ART

Tristan J. Barber, MA, MD, FRCP
Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California